ADCYAP1R1 and neuropathy: Thus, PAC1-agonists mimic EA potential to preserve BM hematopoiesis during chemotherapy and may provide therapeutic advantages to treat cancer patients with advanced neurotoxicity and neuropathies limiting EA efficacy.